However, the main growth driver going forward will be ALKS 2680. This is a once-daily oral OX2R agonist for narcolepsy treatment. ALKS is also now debt‑free with strong cash reserves and ...

It has been about a month since the last earnings report for Alkermes (ALKS). Shares have lost about 6.6% in that time frame, outperforming the S&P 500. Will the recent negative trend continue ...

In this article, we are going to take a look at where Alkermes plc (NASDAQ:ALKS) stands against other best healthcare stocks for long-term investment. In the US, healthcare expenditures and costs ...

Our original story can be found here. The ubiquitous ESP32 microchip made by Chinese manufacturer Espressif and used by over 1 billion units as of 2023 contains undocumented commands that could be ...

In a report released today, Joseph Thome from TD Cowen maintained a Buy rating on Alkermes (ALKS – Research Report), with a price target of $38.00. See what stocks are receiving Strong Buy ...

Alkermes plc (NASDAQ:ALKS – Get Free Report) was the target of a significant increase in short interest in February. As of February 28th, there was short interest totalling 14,010,000 shares ...

Equities research analysts at Royal Bank of Canada began coverage on shares of Alkermes (NASDAQ:ALKS – Get Free Report) in a research report issued on Thursday, MarketBeat.com reports.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vicarious Surgical (RBOT – Research Report), Alkermes (ALKS – Research Report) and Zealand Pharma (ZLDPF ...